Oct 20, 2022 5:00 pm EDT New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
Oct 19, 2022 7:00 am EDT Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
Oct 13, 2022 7:00 am EDT Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
Oct 11, 2022 7:00 am EDT Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
Oct 10, 2022 7:00 am EDT Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
Sep 23, 2022 7:00 am EDT Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
Sep 21, 2022 7:00 am EDT Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
Sep 20, 2022 4:05 pm EDT Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
Sep 13, 2022 7:00 am EDT Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
